Patents Examined by Savitha M Rao
  • Patent number: 10806714
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: October 20, 2020
    Assignee: BIOSUCCESS BIOTECH CO., LTD.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Patent number: 10806725
    Abstract: Small molecule inhibitors of XBP1 splicing by IRE1? are provided, as well as methods for their use in treating or preventing cancer (e.g., endocrine resistant breast cancer), diabetes, and obesity.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: October 20, 2020
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Sivanesan Dakshanamurthy, Milton L. Brown, Robert Clarke, Ayesha N. Shajahan-Haq, Jacqueline Smith
  • Patent number: 10806147
    Abstract: A method for reducing the effects of biological contamination in a hydrocarbon-containing system comprising the steps of continuously adding a formulation comprising tris(hydroxymethyl)phosphine or a tetrakis(hydroxymethyl)phosphonium salt to the system for one day or more; monitoring the efficacy of the continuous treatment by an assessment of the extent to which there is any effect on the environment that is attributable to metabolic activity of active microbes present in the system; wherein the tris(hydroxymethyl)phosphine or tetrakis(hydroxymethyl)phosphonium salt is added at a concentration of from 1 to 30 ppm based on the total volume of aqueous fluid added to the system, and wherein the formulation is added to the system at a stage to minimize incompatibility with any other chemicals that are added to the aqueous fluid.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: October 20, 2020
    Assignee: RHODIA OPERATIONS
    Inventors: Chris Jones, Stephanie Edmunds, Gareth Collins
  • Patent number: 10799490
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 13, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Chong-Hui Gu
  • Patent number: 10799494
    Abstract: The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: October 13, 2020
    Inventors: Giancarlo A. Biagini, Stephen A. Ward, Gemma L. Nixon, Paul M. O'Neill
  • Patent number: 10799472
    Abstract: Compositions and methods for treating parasitic infections are provided. The compositions can include two or more of alpha-pinene, linalyl acetate, para-cymene, and thymol octanoate. The compositions and methods can be effective against, for example, protozoan parasites, helminthic parasites, nematodes, trematodes, flukes, cestodes, and the like. Formulations made from the composition are also provided, including formulations in which the composition is combined with a carrier to form a food product and/or a drink. The formulation can be, for example, a suspension, a solution, or an emulsion in an oily or an aqueous carrier; like wise, the composition can be provided in an encapsulated or microencapsulated form.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 13, 2020
    Assignee: TyraTech, Inc.
    Inventors: Essam Enan, Ahmad Akashe, Anilkumar Gaonkar, Leslie West
  • Patent number: 10799476
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: October 13, 2020
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 10799590
    Abstract: A composition comprising a bitter tastant and at least one sophorolipid and optionally a carrier; wherein the composition is edible and wherein the bitter taste of said bitter tastant is reduced. A method of reducing bitter taste attributed to a bitter tastant in an edible composition, said method comprising adding to said edible composition an effective amount of at least one sophorolipid and optionally a carrier; such that any bitter taste induced by the bitter tastant is reduced.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 13, 2020
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Monell Chemical Senses Center
    Inventors: Daniel Solaiman, Richard D Ashby, Mehmet Hakan Ozdener, Alexander Bachmanov
  • Patent number: 10799510
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: October 13, 2020
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • Patent number: 10793571
    Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: October 6, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Nathanael S. Gray, Jun Qi, Michael R. McKeown, Dennis Buckley
  • Patent number: 10792276
    Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 6, 2020
    Assignee: Amazentis SA
    Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
  • Patent number: 10786482
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: September 29, 2020
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 10786575
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: September 29, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata, Daichi Tanaka
  • Patent number: 10786478
    Abstract: In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: September 29, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Paresh Soni
  • Patent number: 10772864
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequalae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: September 15, 2020
    Assignee: Biosuccess Biotech Co., Ltd.
    Inventors: Hung-Fong Chen, Zheng Tao Han
  • Patent number: 10772868
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: September 15, 2020
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 10772885
    Abstract: The disclosure generally relates to methods of treating an ocular disease, comprising administering an effective amount of a pharmaceutical composition to an eye of a subject in need thereof, wherein the pharmaceutical composition comprises nintedanib, or its salt, derivative, analog or polymorph, or combination thereof. The disclosure also relates to pharmaceutical composition or formulation, which can be used for treating ocular diseases. In another aspect, the disclosure provides method of making the pharmaceutical composition or formulation.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 15, 2020
    Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD.
    Inventors: Shuhua Guo, Jiewen Zhong, Xinting Yuan, Zongren Yao
  • Patent number: 10772886
    Abstract: N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methyl-azetidine-1-sulfonamide (compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 15, 2020
    Assignee: ARDEA BIOSCIENCES, INC.
    Inventors: Payal Nanavati, Jeffrey Miner
  • Patent number: 10765691
    Abstract: Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the increased metabolism of clarithromycin caused by rifabutin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in the metabolism of rifabutin caused by clarithromycin. In an embodiment, the solid dosage form is sufficiently designed to result in a reduction in risk of a subject developing leucopenia or uveitis as a result of rifabutin.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: September 8, 2020
    Assignee: RedHill Biopharma Ltd.
    Inventors: Thomas Julius Borody, Patrick Gosselin
  • Patent number: 10765654
    Abstract: The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 8, 2020
    Assignee: University of Vermont and State Agricultural College
    Inventor: Diane M. Jaworski